Drug intelligence / Profile preview

TEV-288

Development stage: Preclinical
Lead developer: Teva Pharmaceutical Industries
Administration: Intravenous, Subcutaneous

Overview

TEV-288 is an investigational drug candidate currently in the preclinical stage of development by Teva Pharmaceuticals. It is being developed for applications within the field of neuroscience. As of early 2024, the compound is in the discovery or preclinical phase, and Teva has not yet publicly disclosed its specific molecular target, mechanism of action, or the exact neurological indications it is intended to treat. It represents part of Teva's strategic internal research and development efforts to expand its central nervous system (CNS) portfolio alongside other early-stage assets.

Beyond the preview

Go deeper on TEV-288.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TEV-288.

Explore the full profile